Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,504 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Complication Clear all
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339
View directory record Official record
Conditions
Diabetic Cardiomyopathies
Interventions
AT-001, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
28
States / cities
Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 4, 2026, 10:41 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

NCT04419467
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
CSL346, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
25 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Covina, California • Fresno, California • Lomita, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 4, 2026, 10:41 PM EDT
Terminated Phase 4 Interventional Results available

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

NCT01129557
View directory record Official record
Conditions
Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional

A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)

NCT01953757
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Vegan diet and vitamin B12 supplement, Vitamin B12 supplement
Other · Dietary Supplement
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 4, 2026, 10:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

NCT05063734
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level, Aflibercept
Drug
Lead sponsor
Oxurion
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Huntington Beach, California • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 4, 2026, 10:41 PM EDT
Not listed Not applicable Interventional

Real-time Continuous Glucose Monitoring

NCT03326232
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Continuous glucose monitoring
Device
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 4, 2026, 10:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Weight Changes During and After Pregnancy in Women With Gestational Diabetes

NCT02388958
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 4, 2026, 10:41 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

NCT05946798
View directory record Official record
Conditions
Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
Interventions
Acetylcholine, Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 4, 2026, 10:41 PM EDT
Recruiting Phase 4 Interventional

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

NCT07172893
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Interventions
DermaBind TL
Biological
Lead sponsor
HealthTech Wound Care
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
DeLand, Florida • Palm Beach Gardens, Florida • Sweetwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Results available

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

NCT00590044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
insulin glargine+ glulisine, NPH + Regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Phase 3 Interventional

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

NCT05901831
View directory record Official record
Conditions
Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions
Finerenone, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
28
States / cities
Surprise, Arizona • Stanford, California • Vallejo, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 4, 2026, 10:41 PM EDT
Not yet recruiting No phase listed Observational

Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients

NCT06101901
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Phase 1 Interventional

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

NCT00101764
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 10:41 PM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Phase 4 Interventional

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

NCT05922033
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions
Patient-led Insulin (intervention group), Provider-led Insulin (standard care)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

NCT00229437
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
TAK-128, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
40
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional

Spironolactone for Reducing Proteinuria in Diabetic Nephropathy

NCT00498537
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
spironolactone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2008 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Lifestyle Intervention on Gestational Diabetes Management

NCT04861324
View directory record Official record
Conditions
Gestational Diabetes, Type 2 Diabetes, Nutritional and Metabolic Disease
Interventions
Dietary Intervention
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 4, 2026, 10:41 PM EDT
Active, not recruiting Phase 3 Interventional

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

NCT05099770
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT/ rilparencel), Sham Comparator
Biological · Procedure
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
75
States / cities
Huntsville, Alabama • Tucson, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional Results available

Chronic Kidney Disease Clinical Decision Support

NCT03890588
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension, Diabetes
Interventions
CKD enhanced clinical decision support
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
6,295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional Results available

Patient Navigator Intervention for Diabetic Retinopathy

NCT05188703
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Blindness
Interventions
Patient Navigation
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 4, 2026, 10:41 PM EDT
Completed Phase 2 Interventional

Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)

NCT01158131
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Balance after Baby Lifestyle Intervention Program
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 4, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional

Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers

NCT07161830
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Omeza® Complete Matrix, Standard of Care
Device · Other
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Evergreen Park, Illinois • Denham Springs, Louisiana • Leesville, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 4, 2026, 10:41 PM EDT